Navigation Links
Researcher, magnet lab receive $2 million grant to target tuberculosis
Date:1/17/2008

TALLAHASSEE, Fla. -- About 5,000 people around the world die from tuberculosis every day, but no effective new drugs have been developed to combat it in 40 years. Researchers at the National High Magnetic Field Laboratory at Florida State University hope to change that through research made possible by a $2-million grant from the National Institutes of Health.

The award will make it possible for Timothy A. Cross, the Earl Frieden Professor of Chemistry and Biochemistry at FSU, and his team to work toward arming drug developers with a map of the proteins on the bacterias surface that are vital for infection.

Because it isnt often seen in the news in the United States, TB often is overlooked, but it remains one of the globes most deadly infectious diseases. The bacterial infection primarily attacks the lungs, causing 2 million deaths around the world each year. Many of the worlds poor are among its victims, and researchers have raised the alarm about drug-resistant strains of the infection, which, according to the Centers for Disease Control, now account for almost one in five new TB cases.

Some potential new treatments for TB already are being researched, said Cross, who also directs the magnet labs Nuclear Magnetic Resonance program, but there is no knowing if those treatments will survive clinical trials.

Trying to treat so much of the world with the same pharmaceuticals is one of the best ways to develop more resistance to treatment, so its important to come at this from as many angles as possible, he said.

Weve done a preliminary study that shows our work is viable, and we have a lot of preliminary data, Cross said of the research plan, expected to take five years to execute. His team, collaborating with the University of Kansas, the University of Alabama and Case Western Reserve University, will use the magnet labs sophisticated 900 megahertz magnet, as well as other resources, to conduct its research.

Cross thinks the eventual development of a new family of TB drugs could attack the disease in a new and more effective way. He explained that a specific set of proteins appears to be important to TBs ability to attack the body. His team will identify the target proteins that allow bacteria to infect lung tissue. When a drug binds to one of these proteins, it can render the protein ineffective, shutting down its ability to do harm.

We ought to be able to solve the molecular structure of these drug targets, he said. If you know the shape of the protein, then you can design a drug that can bind to it specifically. Getting detailed information about the correct drug target makes it far easier for the pharmaceutical companies to develop safer, more effective treatment.

There has been a lot of interest in our proposal, Cross said, adding, The quality of the graduate students here at FSU made the difference for us. Without a quality research team like this one, this project goes nowhere and our chance of funding work this important would have been zero.


'/>"/>

Contact: Timothy A. Cross
cross@magnet.fsu.edu
850-644-0917
Florida State University
Source:Eurekalert  

Related medicine news :

1. Society of Cardiovascular Magnetic Resonance chooses open access
2. Transcranial magnetic stimulation: An effective treatment for depression
3. Penn research shows transcranial magnetic stimulation effective in treating major depression
4. Bayer HealthCare Pharmaceuticals and MedAssets Supply Chain Systems Sign a Three-Year Agreement for Magnevist(R) Magnetic Resonance Contrast Media
5. A Magnetic Presence: Siemens New MRI Systems Pulling More Patients Toward the Benefits of MR Imaging
6. Stereotaxis Highlights Live Coronary and Peripheral Vascular Cases Performed at TCT With Stereotaxis Magnetic Navigation System
7. Stereotaxis Showcases Interventional Cardiology Capabilities of Niobe Magnetic Navigation System
8. Stereotaxis Highlights New Data on Acute Success in AFib Treatments With Niobe Magnetic Navigation System
9. Novadaqs SPY System receives clearance for use in organ transplant surgery
10. Philadelphia Policeman Helps Amputee Receive Power Wheelchair from The Scooter Store
11. BeneChills RhinoChill System Receives CE Marking for European Commercial Sale
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researcher, magnet lab receive $2 million grant to target tuberculosis
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology: